Document Type : Original Article
Department of Microbiology, Kerman Branch, Islamic Azad University, Kerman, Iran
Immunology of Infectious Diseases Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
Department of Laboratory Sciences, Faculty of Paramedicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
Introduction: Innate immunity cytokines conduct significant functions in the stimulation and induction of liver complications in Hepatitis B infected patients. It has been reported that Royal Jelly (RJ) has important roles in decreasing the pro-inflammatory cytokines in both in vitro and in vivo conditions. This project aimed to investigate the impacts of 1 month RJ administration on interleukin 1 beta (IL-1β), tumor necrosis factor-alpha (TNF-α), and interleukin 6 (IL-6) serum levels in the Hepatitis B patients.
Materials and Methods: In this research, 30 Hepatitis B cases (patients) were entered in order to be under the treatment of RJ for 1 month. Before and after treatment with RJ, Hepatitis B Virus (HBV) copy numbers were evaluated using Real-Time PCR and IL-1β, TNF-α, and IL-6 serum levels were evaluated using the ELISA technique.
Results: The RJ treatment significantly reduced the number of HBV-DNA copies and led to down-regulation of TNF-α and IL-6, which were not substantial. The IL-1β, TNF-α, and IL-6 serum levels were not changed after RJ treatment in both men and women.
Conclusions: Based on the findings of the present study, it seems that RJ plays anti-viral and anti-inflammatory roles in the in vivo conditions in infected patients with HBV.